[go: up one dir, main page]

MX2023008155A - Regimenes de tratamiento con dosis fijas de tamibaroteno. - Google Patents

Regimenes de tratamiento con dosis fijas de tamibaroteno.

Info

Publication number
MX2023008155A
MX2023008155A MX2023008155A MX2023008155A MX2023008155A MX 2023008155 A MX2023008155 A MX 2023008155A MX 2023008155 A MX2023008155 A MX 2023008155A MX 2023008155 A MX2023008155 A MX 2023008155A MX 2023008155 A MX2023008155 A MX 2023008155A
Authority
MX
Mexico
Prior art keywords
tamibarotene
treatment regimens
diagnosed
patient
fixed doses
Prior art date
Application number
MX2023008155A
Other languages
English (en)
Inventor
Maria Rosario
David A Roth
Michael J Kelly
Catherine E Madigan
Original Assignee
Syros Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syros Pharmaceuticals Inc filed Critical Syros Pharmaceuticals Inc
Publication of MX2023008155A publication Critical patent/MX2023008155A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención presenta, inter alia, métodos para tratar (a) un paciente que se ha diagnosticado con un cáncer hematopoyético o (b) una población de pacientes que se han diagnosticado con un cáncer hematopoyético con una dosis fija de tamibaroteno o una sal farmacéuticamente aceptable del mismo. El tamibaroteno se administra diariamente, durante un número prescrito de días, a 8-14 (por ejemplo, 12 mg/día) independientemente del peso o área de superficie corporal del paciente, y se puede administrar como el único agente terapéutico o en combinación con uno o más de los agentes terapéuticos adicionales descritos en la presente.
MX2023008155A 2021-01-08 2022-01-07 Regimenes de tratamiento con dosis fijas de tamibaroteno. MX2023008155A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163135450P 2021-01-08 2021-01-08
PCT/US2022/011670 WO2022150625A1 (en) 2021-01-08 2022-01-07 Treatment regimens with fixed doses of tamibarotene

Publications (1)

Publication Number Publication Date
MX2023008155A true MX2023008155A (es) 2023-07-24

Family

ID=82358338

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023008155A MX2023008155A (es) 2021-01-08 2022-01-07 Regimenes de tratamiento con dosis fijas de tamibaroteno.

Country Status (10)

Country Link
US (1) US20240091183A1 (es)
EP (1) EP4274562A4 (es)
JP (1) JP2024503006A (es)
KR (1) KR20230132496A (es)
CN (1) CN116847835A (es)
AU (1) AU2022206438A1 (es)
CA (1) CA3203995A1 (es)
IL (1) IL304195A (es)
MX (1) MX2023008155A (es)
WO (1) WO2022150625A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2026002056A1 (en) * 2024-06-26 2026-01-02 Beone Pharmaceutical (Suzhou) Co., Ltd. A pharmaceutical formulation comprising solid dispersion of sonrotoclax and a process of preparation thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI471321B (zh) * 2009-06-08 2015-02-01 亞培公司 Ｂｃｌ－２族群抑制劑之口服醫藥劑型
KR20170005069A (ko) * 2014-05-21 2017-01-11 고쿠리츠켄큐카이하츠호진 상교기쥬츠 소고켄큐쇼 암 줄기 세포의 증식 억제제
BR112018070547A2 (pt) * 2016-04-08 2019-02-12 Syros Pharmaceuticals, Inc. agonistas de rara para o tratamento de aml e mds
JP2023542273A (ja) * 2020-08-06 2023-10-06 サイロス ファーマシューティカルズ， インコーポレイテッド Ａｍｌを処置するための治療、ならびにｒａｒａアゴニスト、低メチル化剤、およびｂｃｌ－２阻害剤の使用

Also Published As

Publication number Publication date
WO2022150625A1 (en) 2022-07-14
AU2022206438A1 (en) 2023-07-20
KR20230132496A (ko) 2023-09-15
US20240091183A1 (en) 2024-03-21
IL304195A (en) 2023-09-01
JP2024503006A (ja) 2024-01-24
CN116847835A (zh) 2023-10-03
EP4274562A1 (en) 2023-11-15
EP4274562A4 (en) 2024-11-20
CA3203995A1 (en) 2022-07-14

Similar Documents

Publication Publication Date Title
IL145487A0 (en) Apomorphine and sildenafil composition
CA2402169A1 (en) Formulation and method for treating neoplasms by inhalation
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
MX2021001985A (es) Metodos agnosticos de conteo de plaquetas para tratar la mielofibrosis.
MX2024010637A (es) Nuevas combinaciones terapeuticas para el tratamiento de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2022006566A (es) Tratamientos conjuntos para tratamiento de cancer de mama.
DE602005009176D1 (de) Behandlung von t-zellen-lymphom mittels 10-propargyl-10-deazaaminopterin
MX2023008155A (es) Regimenes de tratamiento con dosis fijas de tamibaroteno.
RU2007119545A (ru) Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743)
MX2024006270A (es) Nueva composicion farmaceutica oral y regimen de dosificacion para la terapia de enfermedades pulmonares intersticiales fibrosantes progresivas.
MX2025002126A (es) Tratamientos con dosis unitarias fijas del anticuerpo actrii
CA2516458A1 (en) Use of kahalalide compounds for the manufacture of a medicament for the treatment of psoriasis
SA94140746B1 (ar) مركب علاجي من /tamoxifen cisplatin للسرطانات في الانسان
MX2024008330A (es) Combinacion de obicetrapib e inhibidor de sglt2
Harwood Kaposi's sarcoma: An update on the results of extended field radiotherapy
RU2853399C1 (ru) Способ повышения эффективности радиотерапии солидных новообразований в эксперименте
NZ331338A (en) Use of 2-(3,4-dimethoxycinnamoyl) aminobenzoic acid for the manufacture of a medicament for the treatment or prevention of restenosis
MX2025001116A (es) Terapia de combinacion contra el cancer que incluye un inhibidor de flt3
McElwain Radiotherapy and Chemotherapy for Colorectal Cancer [Abridged] Chemotherapy in Colorectal Cancer
MX2023005695A (es) Administracion de agonista de sting, inhibidores de puntos de control y radiacion.
Shaharyar et al. A phase II study of gemcitabine concurrent with radiation in locally advanced squamous cell carcinoma of head and neck: A trial of the Cancer Research Group Pakistan
Matthias The Chemotherapy of Malignant Disease: Practical and Experimental Considerations
US20050208149A1 (en) Use of arsenic-containing pharmaceutical composition in combination with radiation therapy for cancer treatment
MX2022002038A (es) Composicion farmaceutica para el tratamiento del insomnio.
Hatschek et al. Continuous versus intermittent prednimustine treatment of non-hodgkin’s lymphoma